ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

PNT POINT Biopharma Global Inc

12,50
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 02:00:00
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
POINT Biopharma Global Inc PNT NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 12,50 02:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
12,50
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
08.1.202413:00EDGAR2Form 15-12G - Securities registration termination [Section..
03.1.202406:15EDGAR2Form EFFECT - Notice of Effectiveness
27.12.202323:41EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202323:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202323:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202323:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202323:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202323:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202323:36EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202323:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27.12.202315:44EDGAR2Form POS AM - Post-Effective amendments for registration..
27.12.202315:43EDGAR2Form POS AM - Post-Effective amendments for registration..
27.12.202315:42EDGAR2Form S-8 POS - Securities to be offered to employees in..
27.12.202314:54EDGAR2Form 8-K - Current report
27.12.202314:31PRNUSLilly Completes Acquisition of POINT Biopharma
18.12.202314:14EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
18.12.202313:30GLOBELantheus and POINT Biopharma Announce Positive Topline..
18.12.202312:45PRNUSLilly Extends Tender Offer to Acquire POINT Biopharma to..
05.12.202312:25IHMARKETNEWSMoody’s Reassesses China, GitLab Exceeds Estimates, Twilio..
04.12.202313:22EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
04.12.202312:45PRNUSLilly Extends Tender Offer to Acquire POINT Biopharma to..
17.11.202313:05EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
17.11.202312:45PRNUSLilly Extends Tender Offer to Acquire POINT Biopharma to..
15.11.202313:00EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
14.11.202322:33PRNUSLilly Announces the Receipt of NRC Consent in Connection..
13.11.202313:30GLOBEPOINT Biopharma Reports Third Quarter 2023 Financial Results..
13.11.202313:15EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08.11.202323:28EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
08.11.202322:56PRNUSLilly Announces Extension of Tender Offer to Acquire POINT..
08.11.202300:33EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02.11.202323:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.11.202321:40EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
27.10.202322:20EDGAR2Form SC 14D9/A - Solicitation, recommendation statements:..
13.10.202313:11EDGAR2Form SC 14D9 - Solicitation, recommendation statements
03.10.202323:24EDGAR2Form SC14D9C - Written communication relating to third party..
03.10.202316:03IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations
03.10.202313:37EDGAR2Form SC14D9C - Written communication relating to third party..
03.10.202313:35EDGAR2Form 8-K - Current report
03.10.202312:45PRNUSLilly to Acquire POINT Biopharma to Expand Oncology..
18.9.202314:00GLOBEPOINT Biopharma and Athebio Announce Partnership to Develop..
14.8.202316:22EDGAR2Form S-8 - Securities to be offered to employees in employee..
14.8.202313:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14.8.202313:30GLOBEPOINT Biopharma Reports Second Quarter 2023 Financial..
14.8.202313:21EDGAR2Form 8-K - Current report
03.8.202322:05EDGAR2Form 8-K - Current report
31.7.202315:00GLOBEITM and POINT Biopharma Expand Global Supply Agreement for..
26.6.202313:45GLOBEPOINT Biopharma and AdvanCell to Collaborate in the..
26.6.202313:30GLOBEPOINT Biopharma Expands Its Research with Next-Generation..
12.6.202314:00GLOBEPOINT Biopharma Announces Appointment of Dr. Bridget Martell..
07.6.202313:00GLOBEPOINT Biopharma to Host Virtual Investor Day on Tuesday,..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock